Inhibikase Therapeutics Reports $16.4 Million Net Loss in Q1 2026, Increases Clinical Development Efforts

Inhibikase Therapeutics, Inc. reported a net loss of $16.4 million for the first quarter of 2026, compared to a net loss of $13.7 million for the same period in 2025, marking a 19.8% increase in losses year-over-year. The company's total expenses for the quarter were approximately $17.8 million, up from $14.6 million in the prior year, driven primarily by a 40.5% increase in selling, general, and administrative expenses, which rose to $7.4 million. Research and development expenses also saw a slight increase of 3.1%, totaling $10.8 million, reflecting ongoing investments in the development of IKT-001, the company's lead product candidate for pulmonary arterial hypertension (PAH).

The company's financial position showed a significant decrease in cash and cash equivalents, which fell to $49.6 million as of March 31, 2026, down from $139.2 million at the end of 2025. This decline was attributed to substantial cash outflows from operating activities, which totaled $12.1 million for the quarter. Inhibikase's marketable securities increased to $120.8 million, up from $39.5 million at the end of the previous year, indicating a strategic shift towards more liquid investments. The accumulated deficit as of March 31, 2026, stood at approximately $159.1 million.

Inhibikase has made notable strides in its clinical development efforts, particularly with the ongoing Phase 3 clinical study, IMPROVE-PAH, which is currently enrolling patients across multiple countries. The company has received regulatory approvals to initiate this study in 16 countries, including the United States and several European nations. In April 2026, Inhibikase announced the enrollment of the first patient in this pivotal trial, which aims to evaluate the efficacy of IKT-001 in treating PAH. The company is also pursuing Orphan Drug Designation for IKT-001 from the U.S. Food and Drug Administration, recognizing the high unmet medical need in this therapeutic area.

Operationally, Inhibikase's employee headcount has increased as the company expands its capabilities to support clinical development and regulatory activities. The company continues to face challenges typical of early-stage biopharmaceutical firms, including the need for substantial funding to support ongoing research and development efforts. Inhibikase has indicated that it may seek additional capital through equity or debt financing to sustain its operations and advance its product candidates. The company believes that its current cash and marketable securities will be sufficient to fund operations for at least the next twelve months, although it acknowledges the inherent uncertainties in its financial projections and operational plans.